Congress mandates free HIV prevention drugs across all insurance types

What it does

This bill requires all major health insurance programs—private insurance, Medicare, Medicaid, CHIP, VA, military TRICARE, and Indian Health Service—to cover HIV prevention medications (like PrEP) and related services without any cost-sharing (copays, deductibles, coinsurance). It also prohibits life, disability, and long-term care insurers from denying coverage or raising premiums based on someone taking HIV prevention medication, funds public education campaigns about PrEP/PEP, and creates a grant program for states and nonprofits to expand access to uninsured and underinsured populations.

Why we flagged it

The bill's core mechanism is a universal coverage mandate for HIV prevention across all insurance types, funded by insurers and federal programs, with no private carve-outs or narrow beneficiaries. It is straightforward public health policy designed to remove financial barriers to prevention.

What the text implies

• Section 6 (patient confidentiality) allows family plan enrollees to access PrEP without other family members being informed—a privacy protection that may reduce stigma-driven disclosure but could complicate family health discussions.
• The bill's prohibition on preauthorization (section 3(a)(3)) allows plans to require preauth only if they offer a therapeutically equivalent drug without preauth—this creates a loophole for plans to impose preauth on all PrEP drugs if none are preauth-free.
• Section 4's prohibition on insurance discrimination applies only to life, disability, and long-term care insurance—health insurance discrimination based on PrEP use is not explicitly addressed, though coverage mandates may implicitly prevent it.
• The grant program (section 7) is authorized but not appropriated—actual funding depends on future congressional action, so access expansion for uninsured/underinsured populations is contingent on appropriations.
• Section 10(a)(2) requires HHS to develop 'billing and coding documents based on stakeholder consensus'—this defers technical implementation to industry input, which could affect how quickly and uniformly coverage is operationalized.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people gain free access to proven HIV prevention medications across all insurance types, eliminating cost as a barrier to prevention. The bill also protects people taking PrEP from discrimination in life and disability insurance, and funds outreach to underserved communities—all concrete public health gains with no offsetting cost to citizens.

Who stands to gain

• Pharmaceutical manufacturers of PrEP drugs (increased demand from expanded coverage)
• Clinical laboratories and diagnostic providers (increased testing and monitoring services)
• Healthcare providers and clinics (increased patient volume for PrEP-related services)

Named in the bill

Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare & Medicaid Services, Department of Labor, Department of the Treasury, Department of Veterans Affairs, Department of Defense, Indian Health Service, Food and Drug Administration, State insurance commissioners, Federally qualified health centers, Community-based organizations

Where it stands

29 cosponsors: 29 Democrats.

• Mar 4, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 4, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $40,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Tina Smith, the sponsor, reported $-40,500 in PAC receipts in the 2026 cycle.

• Hiv and Hepatitis Policy Institute — $40,000 on 1 filing

Lobbying Disclosure Act filings through Jul 15, 2026. A filing shows who paid to lobby on a bill it names, not what changed.